Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Read More…
Industry, Sector and Symbol
Industry Private households
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-18-6578-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$89.14 million
Profitability
Miscellaneous
Employees432
Next Earnings DateN/A
OptionableNot Optionable
Oxford BioMedica (OTCMKTS:OXBDF) Frequently Asked Questions
What is Oxford BioMedica's stock symbol?
Oxford BioMedica trades on the OTCMKTS under the ticker symbol "OXBDF."
What price target have analysts set for OXBDF?
1 brokers have issued 12-month price objectives for Oxford BioMedica's stock. Their forecasts range from $14.50 to $14.50. On average, they expect Oxford BioMedica's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 111.7% from the stock's current price. View Analyst Price Targets for Oxford BioMedica.
What is the consensus analysts' recommendation for Oxford BioMedica?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford BioMedica.
What are Wall Street analysts saying about Oxford BioMedica stock?
Here are some recent quotes from research analysts about Oxford BioMedica stock:
- 1. According to Zacks Investment Research, "Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. " (9/12/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and 1450p price target. Our price target is based on our clinical net present value (NPV) model, which derives value primarily from Novartis’ CTL019 (lentiviral production and royalty). This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (9/4/2019)
Has Oxford BioMedica been receiving favorable news coverage?
Media headlines about OXBDF stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oxford BioMedica earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Oxford BioMedica.
Who are some of Oxford BioMedica's key competitors?
Some companies that are related to Oxford BioMedica include TOKUYAMA CORP/ADR (TKYMY), PETROFAC LTD/ADR (POFCY), DOMINOS PIZZA U/ADR (DPUKY), INDRA SISTEMAS/ADR (ISMAY), CAIRN ENERGY PL/ADR (CRNCY), JAPAN STL WORKS/ADR (JPSWY), Schaeffler (SCFLF), Clinigen Group (CLIGF), Acacia Mining (ABGLF), Hochschild Mining (HCHDF), Cybg (CBBYF), Jungheinrich (JGHAF), OUTOKUMPU OYJ/ADR (OUTKY), FIH MOBILE LTD/ADR (FXCNY) and Gree,Inc. (GREZF).
What other stocks do shareholders of Oxford BioMedica own?
Who are Oxford BioMedica's key executives?
Oxford BioMedica's management team includes the folowing people:
- Mr. John Dawson, CEO & Exec. Director (Age 59)
- Mr. Stuart Paynter, CFO & Director
- Mr. Timothy William Watts, Exec. Officer (Age 61)
- Mr. Peter Nolan, Consultant (Age 66)
- Mr. Nick Page, Chief Operations Officer
How do I buy shares of Oxford BioMedica?
Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oxford BioMedica's stock price today?
One share of OXBDF stock can currently be purchased for approximately $6.85.
How big of a company is Oxford BioMedica?
What is Oxford BioMedica's official website?
How can I contact Oxford BioMedica?
Oxford BioMedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000.
MarketBeat Community Rating for Oxford BioMedica (OTCMKTS OXBDF)
MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXBDF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXBDF will underperform the S&P 500 over the long term. You may vote once every thirty days.
